In general, a platform or oral first line DMT (fl-DMT) was offered unless any of the following circumstances occurred: (i) two clinical attacks in a year, (ii) a clinical attack and/or a new gadolinium-enhanced lesion (GEL) within a year, or (iii) a disabling clinical attack with residual EDSS of at least 2 points in the pyramidal system
Yes, but only as a research chemical
Preclinical research explores its remarkable ability to promote synaptogenesis , dendritic spine growth, and cognitive enhancement
Research teams frequently include 5-Amino-1MQ within analytical programs that emphasize controlled observation, standardized procedures, and scientific investigation
Kits, and blends, cost more in total but can work out cheaper per milligram